Becton Dickinson and Co (NYSE:BDX) VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Becton Dickinson and Co (NYSE:BDX) traded down 0.33% during midday trading on Friday, reaching $186.16. The company had a trading volume of 643,163 shares. The firm has a 50-day moving average of $183.68 and a 200-day moving average of $177.26. Becton Dickinson and Co has a 12 month low of $161.29 and a 12 month high of $187.69. The stock has a market cap of $39.71 billion, a P/E ratio of 30.92 and a beta of 1.00.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.07. The business had revenue of $2.97 billion during the quarter, compared to analysts’ expectations of $2.92 billion. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.18 earnings per share. On average, equities analysts expect that Becton Dickinson and Co will post $9.44 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Shareholders of record on Friday, June 9th will be given a dividend of $0.73 per share. The ex-dividend date is Wednesday, June 7th. This represents a $2.92 annualized dividend and a yield of 1.56%. Becton Dickinson and’s dividend payout ratio is currently 48.42%.

WARNING: “Becton Dickinson and Co (BDX) VP Sells $5,349,714.70 in Stock” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/05/26/becton-dickinson-and-co-bdx-vp-sells-5349714-70-in-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. Crestwood Advisors Group LLC purchased a new position in shares of Becton Dickinson and during the first quarter valued at approximately $101,000. North Star Investment Management Corp. increased its position in shares of Becton Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Becton Dickinson and during the first quarter valued at approximately $105,000. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in shares of Becton Dickinson and during the third quarter valued at approximately $108,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Becton Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Institutional investors and hedge funds own 82.30% of the company’s stock.

BDX has been the subject of several recent analyst reports. Jefferies Group LLC restated a “buy” rating and set a $200.00 target price on shares of Becton Dickinson and in a research note on Wednesday, March 29th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price objective for the company in a research report on Tuesday, April 11th. Royal Bank of Canada reiterated a “hold” rating and issued a $177.00 price objective on shares of Becton Dickinson and in a research report on Thursday, April 13th. Finally, Evercore ISI upgraded Becton Dickinson and from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $186.09.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

12 Month Chart for NYSE:BDX

Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.